- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.08. | Epicrispr raises $90M to rewrite treatment of rare muscle disease | ||
| 11.08. | Zydus' Sentynl pens $475M deal for Mereo's phase 3-ready rare genetic lung disease drug | ||
| 11.08. | Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer | ||
| 10.08. | MoonLake's nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial | ||
| 10.08. | Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies | ||
| 10.08. | Sionna's cystic fibrosis flop sends stock down 90%, but a 'significant positive' for Vertex | ||
| 10.08. | AbCellera women's health data top 'most aggressive upside scenario,' putting Astellas and Bayer on notice | ||
| 10.08. | Silence brings the noise to Takeda with phase 2 blood cancer win | ||
| 10.08. | Sobi pens $580M deal for Innate's skin cancer drug ahead of phase 3 push | ||
| 10.08. | Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program | ||
| 10.08. | aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug | ||
| 07.08. | Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy | ||
| 07.08. | BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts | ||
| 07.08. | BioMarin axes $270M rare disease asset after missing phase 3 endpoint | ||
| 07.08. | Novo Nordisk's CFO on the oral Wegovy rollout and beyond | ||
| 06.08. | Double shot of Vistagen's anxiety nasal spray can't beat placebo in ph. 2 trial | ||
| 06.08. | Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug | ||
| 06.08. | BioVie's stock sinks 50% as company uses composite endpoint to make case for Parkinson's program | ||
| 06.08. | Braveheart Bio charges past expectations with $382.5M IPO to fund cardio drug from Hengrui | ||
| 06.08. | Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday | ||
| 06.08. | Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027 | ||
| 05.08. | Sanofi suspends chronic lung disease phase 2 study, tied to 'strategic business reasons' | ||
| 05.08. | Lilly drops another gene therapy trial from $1B Prevail buyout | ||
| 05.08. | Novo CEO accepts 'couple of setbacks' in R&D as CagriSema posts more mixed data | ||
| 05.08. | Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.